US2015196503A1PendingUtilityA1
Co-crystals of tramadol and coxibs
Est. expiryOct 17, 2028(~2.2 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 3/10A61P 25/04A61P 25/00A61P 29/00A61P 19/00A61P 21/00A61P 19/02A61K 31/635C07B 2200/13C07C 59/64A61K 31/135C07C 217/74A61K 9/16A61K 31/137C07C 2602/10C07C 2601/14A61K 45/06C07D 231/12A61K 31/192A61P 25/02A61K 31/415
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Claims
exact text as granted — not AI-modified1 . A co-crystal comprising (rac)-tramadol.HCl and celecoxib in a molecular ratio of 1:1, characterized in that it has an orthorhombic unit cell with the following dimensions:
a=11.0323(7) Å b=18.1095(12) Å c=17.3206(12) Å.
2 . A co-crystal according to claim 1 , characterized in that it shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm −1 .
3 . Pharmaceutical composition characterized in that it comprises a therapeutically effective amount of the co-crystal according to claim 1 in a physiologically acceptable medium.
4 . Pharmaceutical composition characterized in that it comprises a therapeutically effective amount of the co-crystal according to claim 2 in a physiologically acceptable medium.Join the waitlist — get patent alerts
Track US2015196503A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.